FDA Chief Urges Enhanced Oversight for AI in Healthcare Systems

FDA Commissioner Robert Califf has expressed the need for better oversight of artificial intelligence (AI) in healthcare, particularly in the post-market phase, due to the adaptive nature of AI systems that require continuous validation. He highlighted that many health systems struggle to monitor AI algorithms effectively, which is critical for applications like stroke prediction. A major challenge to oversight is the fragmented healthcare data landscape, where essential information is often siloed, complicating AI performance assessments. Califf emphasized the necessity for a collaborative, data-driven approach to improve transparency and accountability in AI management within health systems.

Opens on HealthExec